Cell-Free DNA and Mitochondria in Parkinson’s Disease
Open Access
- 30 November 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (23) , 11615
Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by the gradual and irreversible loss of neurons, especially within the substantia nigra region of the midbrain. Early and accurate diagnosis remains a significant challenge in both research and clinical practice. This difficulty is further compounded by the substantial clinical and molecular heterogeneity of PD, emphasizing the urgent need for reliable biomarkers to enhance diagnostic precision and guide therapeutic strategies. One promising candidate biomarker is cell-free DNA (cfDNA), comprising short DNA fragments composed of mitochondrial (cf-mtDNA) and nucleus-derived (cf-ntDNA) DNA. cfDNA is released into body fluids through physiological or pathological processes such as apoptosis, necrosis, NETosis, or active secretion. The presence of cfDNA in human biological fluids has been utilized for years in oncology and prenatal medicine and, more recently, it has gained attention as a non-invasive diagnostic tool in the context of neurodegenerative diseases such as PD. This review article aims to provide a comprehensive overview of the current knowledge on the origin of cfDNA, highlighting the roles of the mitochondria and cf-mtDNA in PD, mitochondria quality control, and neuroinflammation in cfDNA biogenesis. The review collates available research on cfDNA types in human serum, plasma, and CSF, sequence analysis, and its potential application as a biomarker in the diagnosis and monitoring of PD, contributing to the ongoing search for non-invasive biomarkers of neurodegenerative diseases.Keywords
This publication has 135 references indexed in Scilit:
- CNS Mitochondria‐Derived Vesicle in Blood: Potential Biomarkers for Brain Mitochondria DysfunctionAnnals of Clinical and Translational Neurology, 2025
- Mitochondria‐Related Genome‐Wide Mendelian Randomization Identifies Putatively Causal Genes for Neurodegenerative DiseasesMovement Disorders, 2025
- Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson DiseaseMovement Disorders, 2021
- Cell-Free DNA: Applications in Different Diseases2018
- High-sensitivity C-reactive protein and high mobility group box-1 levels in Parkinson’s diseaseNeurological Sciences, 2018
- Alpha-synuclein mitochondrial interaction leads to irreversible translocation and complex I impairmentArchives of Biochemistry and Biophysics, 2018
- Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent MitophagyThe American Journal of Human Genetics, 2016
- Characterization of the cell-free DNA released by cultured cancer cellsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2016
- Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early‐stage Parkinson's diseaseAnnals of Neurology, 2015
- Molecular pathogenesis of polymerase gamma–related neurodegenerationAnnals of Neurology, 2014